A key patent that encompasses the therapeutic application scope of the Click-to-Release platform has been granted in the US (US 10,967,069 B2), further strengthening Tagworks’ IP portfolio.

The patent titled “BIO-ORTHOGONAL DRUG ACTIVATION”, covers the invention of the pyridazine elimination reaction that underlies the Click-to-Release approach. The patent protects a broad scope of TCO linkers and tetrazine activators and their application in selective on-target release and activation of a wide range of constructs, including small molecule prodrugs, antibody-drug conjugates, and caged proteins.